Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 Sales of NARCAN® Nasal Spray for Opioid Overdose

Stock Information for Opiant Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Opiant Pharmaceuticals Inc.

Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC
Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC
Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPNT, CBIO
OPIANT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Opiant Pharmaceuticals, Inc. - OPNT
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPNT, IMGO, FORG, USER
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPNT, IMGO, SAL
SHAREHOLDER ALERT: Weiss Law Reminds EQ, IMGO, MTCR, and OPNT Shareholders About Its Ongoing Investigations

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.